SCHEMBL6703971

SCHEMBL6703971

Cc1cccc(C(CCN)c2ccccc2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 5/20 0.67
HTR2A P28223 4/20 0.52
CYP19A1 P11511 3/20 0.50
LMNA P02545 2/20 0.46
MAPT P10636 1/20 0.46
ALOX12 P18054 1/20 0.46
HTT P42858 1/20 0.46
ACP3 P15309 1/20 0.45
TAAR1 Q96RJ0 2/20 0.44
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C19 P33261 2/20 0.42
KCNH2 Q12809 2/20 0.42
KIF11 P52732 2/20 0.42
CYP2C9 P11712 1/20 0.42
CHRM2 P08172 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CHRM1 P11229 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6000683 0.86 ACHE (0.50) HRH1CYP19A1TAAR1SLC6A2SLC6A4
SCHEMBL3910832 0.85 TAAR1 (0.64) HRH1HTR2ACYP19A1ACP3TAAR1
SCHEMBL6546957 0.83 CYP19A1 (0.51) HRH1HTR2ACYP19A1LMNAMAPT
SCHEMBL158098 0.82 HRH1 (1.00) HRH1HTR2ALMNAALOX12HTT
SCHEMBL27466804 0.81 CYP19A1 (0.50) HRH1HTR2ACYP19A1LMNAMAPT
SCHEMBL20274525 0.81 TAAR1 (0.47) HRH1HTR2ACYP19A1ACP3TAAR1
SCHEMBL4381016 0.80 TAAR1 (0.56) HTR2ACYP19A1MAPTACP3TAAR1
SCHEMBL6546797 0.80 CYP19A1 (0.56) HRH1HTR2ACYP19A1LMNAMAPT
Ammonia Solution, Strong SCHEMBL3795841 0.80 HRH1 (0.95) HRH1HTR2ALMNAALOX12HTT
Iodide SCHEMBL28361744 0.80 HRH1 (0.95) HRH1HTR2ALMNAALOX12HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1088585-C Compound active at a novel site on receptor-operated calcium channels usefull for treatment of neurological disorders and diseases NPS PHARMACEUTICAL CO LTD (US) 2002-08-07 CN claimed
EP-0743853-B1 COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES NPS PHARMA INC (US) 2001-05-02 EP claimed
EP-2855421-B1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES CRYSTAL PHARMA SAU (ES) 2018-03-21 EP disclosed
JP-2004002437-A COMPOUND ACTIVE AT NEW POSITION ON RECEPTOR-OPERATED CALCIUM CHANNEL USEFUL FOR TREATING NEUROPRAXIA AND NEUROPATHY NPS PHARMACEUT INC 2004-01-08 JP disclosed
EP-0743853-B1 COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES NPS PHARMA INC (US) 2001-05-02 EP disclosed